Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ.

Am J Gastroenterol. 2012 Sep;107(9):1409-22. doi: 10.1038/ajg.2012.218. Epub 2012 Aug 14.

2.

Methotrexate for induction of remission in refractory Crohn's disease.

McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG.

Cochrane Database Syst Rev. 2014 Aug 6;(8):CD003459. doi: 10.1002/14651858.CD003459.pub4. Review.

PMID:
25099640
3.

Methotrexate for induction of remission in refractory Crohn's disease.

McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD003459. doi: 10.1002/14651858.CD003459.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;8:CD003459.

PMID:
23235598
4.

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.

Gordon M, Taylor K, Akobeng AK, Thomas AG.

Cochrane Database Syst Rev. 2014 Aug 1;(8):CD010233. doi: 10.1002/14651858.CD010233.pub2. Review.

PMID:
25081347
5.

Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.

Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA.

Clin Gastroenterol Hepatol. 2014 Sep;12(9):1443-51; quiz e88-9. doi: 10.1016/j.cgh.2014.01.021. Epub 2014 Jan 22. Review.

PMID:
24462626
6.

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.

Chande N, Townsend CM, Parker CE, MacDonald JK.

Cochrane Database Syst Rev. 2016 Oct 26;10:CD000545. Review.

PMID:
27783843
7.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

8.

Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.

Feagan BG, Enns R, Fedorak RN, Panaccione R, Paré P, Steinhart AH, Wild G.

Can J Clin Pharmacol. 2001 Winter;8(4):188-98. Review.

PMID:
11743591
9.

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.

Chande N, Tsoulis DJ, MacDonald JK.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD000545. doi: 10.1002/14651858.CD000545.pub4. Review. Update in: Cochrane Database Syst Rev. 2016 Oct 26;10 :CD000545.

PMID:
23633304
10.

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.

Keating GM, Perry CM.

BioDrugs. 2002;16(2):111-48. Review.

PMID:
11985485
11.

The risks of post-operative complications following pre-operative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: a systematic review and meta-analysis.

Rosenfeld G, Qian H, Bressler B.

J Crohns Colitis. 2013 Dec;7(11):868-77. doi: 10.1016/j.crohns.2013.01.019. Epub 2013 Mar 5. Review.

12.

Transcending conventional therapies: the role of biologic and other novel therapies.

Sandborn WJ.

Inflamm Bowel Dis. 2001 May;7 Suppl 1:S9-16. Review.

PMID:
11380043
13.

How to improve the safety of biologic therapy in Crohn's disease.

Ferkolj I.

J Physiol Pharmacol. 2009 Dec;60 Suppl 7:67-70. Review.

14.

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.

Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK.

Cochrane Database Syst Rev. 2015 Oct 30;(10):CD000067. doi: 10.1002/14651858.CD000067.pub3. Review.

PMID:
26517527
15.

Infliximab for pediatric Crohn's disease.

Hoffman I, Vermeire S, Van Assche G, Rutgeerts P.

Drugs Today (Barc). 2008 Aug;44(8):615-28. doi: 10.1358/dot.2008.44.8.1248345. Review.

PMID:
18846272
16.

Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: a rare clinical presentation and review of the literature.

Mohammad F, Vivekanandarajah A, Haddad H, Shutty CM, Hurford MT, Dai Q.

BMJ Case Rep. 2014 May 19;2014. pii: bcr2013203318. doi: 10.1136/bcr-2013-203318. Review.

Supplemental Content

Support Center